The Economic Times

Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impact

Sun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affordable for low-income Americans. Analysts believe the financial impact on Sun Pharma will be minimal. The company's US revenue contribution is significant, reinforcing its growth strategy. This pact recognizes Sun Pharma's investment in the American market.